Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C

• Published in: Gastroenterology (New York, N.Y. 1943) Vol. 138; no. 1; p. 108
• Main Authors: Rumi, Maria Grazia, Aghemo, Alessio, Prati, Gian Maria, D'Ambrosio, Roberta, Donato, Maria Francesca, Soffredini, Roberta, Del Ninno, Ersilio, Russo, Antonio, Colombo, Massimo
• Format: Journal Article
• Language: English
• Published: United States 01.01.2010
• Subjects: Adolescent; Adult; Aged; Antiviral Agents - administration & dosage; Antiviral Agents - adverse effects; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus - drug effects; Hepacivirus - genetics; Hepatitis C, Chronic - drug therapy; Humans; Interferon-alpha - administration & dosage; Interferon-alpha - adverse effects; Logistic Models; Male; Middle Aged; Polyethylene Glycols - administration & dosage; Polyethylene Glycols - adverse effects; Recombinant Proteins; Ribavirin - administration & dosage; Ribavirin - adverse effects; Young Adult

Ribavirin (RBV) combined with either pegylated interferon (PegIFN) alpha2a or PegIFNalpha2b is the standard of care for chronic hepatitis C virus (HCV) infection. Due to the lack of head-to-head studies, the 2 PegIFNs have not been directly compared. The endpoints of our study were safety and antivi...